Because an anticoagulant medicine is intended to be used for the prevention and treatment of embolism and non-hemorrhagic stroke, rising rates of these medical diseases are likely to drive rivaroxaban market growth over the forecast period. According to the Centres for Disease Control and Prevention (CDC) estimates from 2015, around 900,000 persons in the United States are projected to be afflicted by venous thromboembolism each year. Furthermore, the number of affected individuals in the United States is predicted to rise by 5% to 8% as a result of many genetic risk factors, such as the condition known as hereditary thrombophilia.
The global Rivaroxaban Market was estimated to be worth US$ 5,653 million in 2017 and is expected to grow at a 1.5% CAGR from 2018 to 2026 due to patent expiry during the forecast period.
Leading Companies of Rivaroxaban Industry:
Janssen Pharmaceuticals, Inc:
1. In Raritan, New Jersey, there is a portfolio of drug testing patents. The patent covers diagnostic methods used to determine drug levels in individuals receiving anti-psychotic medicine. Headquarters are in the United States. Anakuria Therapeutics (February 2022), Benevir (May 2018), and XO1 (March 2015) are the most recent acquisitions.
Dr. Reddy’s Laboratories Ltd:
2. Established in 1984. Dr. Headquarters are located in Hyderabad, Telangana. Reddy's is one of the world's major generic medication makers. It has a strong presence in North America, which accounts for about half of its generics sales, and it also serves India (22% of its generics sales), Russia (12%), and select European and Latin American countries. Dr. Reddy's also has a strong portfolio of injectables, which account for 25% of its North American sales. Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., announced on February 27, 2023 that it has entered into a formal deal to purchase Mayne Pharma Group Limited's U.S. generic prescription product portfolio.